Serum LL-37 levels correlate with the efficacy of i.v. cyclophosphamide pulse for skin sclerosis and interstitial lung disease in systemic sclerosis

J Dermatol. 2017 Apr;44(4):468-469. doi: 10.1111/1346-8138.13553.

Authors

Takehiro Takahashi¹, Yoshihide Asano¹, Takashi Taniguchi¹, Ayumi Yoshizaki¹, Shinichi Sato¹

Affiliation

¹ Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.

PMID: 28378437
DOI: 10.1111/1346-8138.13553

No abstract available

MeSH terms

Administration, Oral
Aged
Antimicrobial Cationic Peptides / blood*
Cathelicidins
Cyclophosphamide / pharmacology
Cyclophosphamide / therapeutic use*
Female
Fibrosis
Humans
Immunosuppressive Agents / pharmacology
Immunosuppressive Agents / therapeutic use*
Infusions, Intravenous
Lung Diseases, Interstitial / blood
Lung Diseases, Interstitial / drug therapy*
Lung Diseases, Interstitial / pathology
Middle Aged
Prednisolone / therapeutic use
Scleroderma, Systemic / blood
Scleroderma, Systemic / drug therapy*
Scleroderma, Systemic / pathology
Skin / drug effects
Skin / pathology
Treatment Outcome

Substances

Antimicrobial Cationic Peptides
Immunosuppressive Agents
Cyclophosphamide
Prednisolone
Cathelicidins